Decreased Survival in Heart Failure Patients: Cilostazol is contraindicated in patients with congestive heart failure of any severity. Cilostazol and several of its metabolites are phosphodiesterase III inhibitors. Several drugs with this pharmacologic effect have caused decreased survival compared to placebo in patients with class III to IV congestive heart failure.
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign Out
